Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on February 25, 2021. The report details corporate governance actions taken at a Special Meeting of Stockholders held on the same date at the company's principal executive offices in Florham Park, New Jersey.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate structural changes and stockholder voting results.
Material Changes
- Authorized Share Increase: The Company amended its Second Amended and Restated Certificate of Incorporation to increase the number of authorized common shares from 80,000,000 to 160,000,000.
- Stockholder Approval: Stockholders approved the issuance of common stock upon the conversion of Series D Preferred Stock issued in a private placement on December 28, 2020, in accordance with Nasdaq Listing Rule 5635(d).
- Voting Statistics: As of the record date (December 28, 2020), there were 45,409,104 shares outstanding. At the meeting, 29,993,317 shares were represented, constituting a quorum.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The primary purpose of the document is to disclose the results of the stockholder vote and the amendment to the Certificate of Incorporation.
Key Facts for Investor Verification
- Verify the impact of the Series D Preferred Stock conversion on total outstanding share count and potential dilution.
- Confirm the updated authorized share count of 160,000,000 common shares.
- Review the specific terms of the Series D Preferred Stock issued on December 28, 2020, to understand the conversion mechanics.
- Note that the filing does not include updated financial statements; refer to the most recent 10-K or 10-Q for financial health.